Abstract: AIM: To investigate the clinical effect and safety of combining edaravone with breviscapine in treatment of patients with acute cerebral infarction (ACI).METHODS: Ninety-seven ACI cases were randomly divided into treatment group and control group.The control group receiving the treatment of Fufang Danshen injection 20 mL+0.9%NS 250 mL iv gtt qd and 0.9%NS 15mL+0.9%NS 250mL iv gtt b.i.d for 14d, while the treatment group was treated with breviscapine injection 50 mg+0.9%NS 250 mL iv gtt qd and edaravone injection 30 mg+0.9%NS 250 mL iv gtt b.i.d for 14 d.RESULTS: The improvement of the clinic neurological function deficient score at 7, 14 and 21 d after treatment in treatment group was obviously better than that in control group(P<0.05).The improving rate in treatment group was significantly higher than that in control group (70.8% vs 40.8%, P<0.01).The total effective rate in treatment group was significantly higher than that in control group (91.7% vs 63.3%, P<0.01).The score of MRS in two groups were improved at 90 d after treatment, but the improvement in treatment group was more obvious(P<0.05).The treatment group had few side effect occurred.CONCLUSION: Combining edaravone with breviscapine can effectively improve the neurological function and the living ability of patients with ACI.

Key words: acute cerebral infarction, edaravone, breviscapine, living ability